Patents by Inventor Chad Albert COWAN

Chad Albert COWAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods for treatment of glycogen storage disease type 1A
    Patent number: 11866727
    Abstract: The present application provides materials and methods for treating a patient with Glycogen Storage Disease type 1a (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: January 9, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Ante Sven Lundberg, Kirsten Leah Beaudry
  • Materials and methods for treatment of alpha-1 antitrypsin deficiency
    Patent number: 11851653
    Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 26, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Jeffrey Li, Ante Sven Lundberg, Matthias Johannes John, Jeffrey William Stebbins, Thao Thi Nguyen
  • Materials and Methods for Treatment of Duchenne Muscular Dystrophy
    Publication number: 20230181766
    Abstract: The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.
    Type: Application
    Filed: May 19, 2022
    Publication date: June 15, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ami Meda Kabadi, Chad Albert Cowan, Ante Sven Lundberg
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220211874
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: February 2, 2022
    Publication date: July 7, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-Ching Lin, Bibhu Prasad Mishra, Elizabeth Paik, Andrew Kernytsky, Todd Douglass Borland
  • Materials and methods for treatment of Duchenne Muscular Dystrophy
    Patent number: 11369692
    Abstract: The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: June 28, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ami Meda Kabadi, Chad Albert Cowan, Ante Sven Lundberg
  • MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS
    Publication number: 20220008558
    Abstract: Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 13, 2022
    Inventors: Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
  • MATERIALS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND/OR FRONTAL TEMPORAL LOBULAR DEGENERATION
    Publication number: 20210260219
    Abstract: The present application provides materials and methods for treating a patient with Amyotrophic Lateral Sclerosis (ALS) and/or Frontaltemporal Lobular Degeneration (FTLD), both ex vivo and in vivo. In addition, the present application provides materials and methods for editing to modulate the expression, function or activity of the C9ORF72 gene in a cell by genome editing.
    Type: Application
    Filed: December 22, 2016
    Publication date: August 26, 2021
    Inventors: Chad Albert Cowan, Ami Meda Kabadi, Ante Sven Lundberg
  • Materials and methods for treatment of hereditary haemochromatosis
    Patent number: 11083799
    Abstract: Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: August 10, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210180091
    Abstract: Provided are materials and methods for treating patients with hemoglobinopathies, either ex vivo or in vivo. Also provided are materials and methods for deleting and/or mutating a portion of a human beta globin locus on chromosome 11 and one or more of: a BCL11 A gene on chromosome 2, and a DNA sequence that encodes a transcriptional control region of the BCL11 A gene on chromosome 2, in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF) in the genome-edited human cells.
    Type: Application
    Filed: October 26, 2018
    Publication date: June 17, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra, Chad Albert Cowan, Ante Sven Lundberg, Samarth Kulkarni, Todd Douglass Borland
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20200330609
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 22, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle l-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglass Borland
  • MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A
    Publication number: 20190382798
    Abstract: The present application provides materials and methods for treating a patient with Glycogen Storage Disease type la (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.
    Type: Application
    Filed: November 7, 2016
    Publication date: December 19, 2019
    Inventors: Chad Albert COWAN, Roman Lvovitch BOGORAD, Ante Sven LUNDBERG, Kirsten Leah BEAUDRY
  • MATERIALS AND METHODS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    Publication number: 20190374655
    Abstract: The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.
    Type: Application
    Filed: October 28, 2016
    Publication date: December 12, 2019
    Inventors: Ami Meda KABADI, Chad Albert COWAN, Ante Sven LUNDBERG
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190201553
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: March 18, 2019
    Publication date: July 4, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglas Borland
  • MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS
    Publication number: 20190076551
    Abstract: Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 14, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
  • MATERIALS AND METHODS FOR TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY (SCID) OR OMENN SYNDROME
    Publication number: 20190038771
    Abstract: The present application provides materials and methods for treating a patient with severe combined immunodeficiency (SCID) or Omenn Syndrome, both ex vive and in vive. In addition, the present application provides materials and methods for editing to modulate the expression, function or activity of the Recombination Activating Gene 1 (RAG1) gene in a cell by genome editing.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 7, 2019
    Inventors: Thomas James CRADICK, Chad Albert COWAN, Ante Sven LUNDBERG, Gregory Joseph COST
  • MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
    Publication number: 20190010490
    Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.
    Type: Application
    Filed: December 1, 2016
    Publication date: January 10, 2019
    Inventors: Chad Albert COWAN, Roman Lvovitch BOGORAD, Jeffrey LI, Ante Sven LUNDBERG, Matthias Johannes JOHN, Jeffrey William STEBBINS, Thao Thi NGUYEN
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20180273609
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: November 4, 2016
    Publication date: September 27, 2018
    Applicant: CRISPR Therapeutics AG
    Inventors: Matthew Hebden PORTEUS, Melanie Ruth ALLEN, Chad Albert COWAN, Ante Sven LUNDBERG, Michelle I-Ching LIN, Jeffrey LI, Thao Thi NGUYEN